Investing in transformational technologies that address unmet health and economic needs
Ablative Solutions, Inc., located in Kalamazoo, MI, is focused on designing a transcatheter chemo-denervation treatment for the renal nerves to alleviate refractory hypertension.
Amplitude Vascular Systems, Inc. (AVS) is an early-stage medical device company developing an Intravascular Lithotripsy (IVL) balloon catheter for peripheral and coronary interventional procedures. The technology was born in an incubator program at the University of Michigan.
Aria CV, Inc. is developing a cardiovascular medical device to treat patients with pulmonary hypertension, or high blood pressure in the arteries of the lungs. Pulmonary hypertension causes increased workload on the heart, eventually leading to right-sided heart failure. Employing a novel mechanism, Aria CV’s device has the potential to improve outcomes by reducing right ventricular workload.
Autonomix Medical, Inc. was founded in 2014 as a collaboration between BioStar Ventures and a world-renowned group of cardiologists and engineers. The company is developing novel electrophysiologic technology for human autonomic neural sensing with multiple possible clinical applications. One purpose is to determine optimal patient selection for successful renal denervation and to intra-procedurally detect denervation efficacy in real time.
CathWorks Ltd. is developing an image-based fractional flow reserve (FFR) measurement designed to replace the pressure wire-based, drug-induced measurement currently performed. The CathWorks angiogram-based FFR (FFRangio) technology provides a less-invasive assessment tool to improve real-time functional assessment that guides treatment decisions and to make coronary catheterization procedures safer, shorter, more accurate, and more comprehensive.
Foldax, Inc. is developing synthetic heart valves with the goal of delivering non-thrombogenic aortic and mitral valves at dramatically lower costs versus existing artificial and tissue valves.
Greenbrook TMS, Inc. (NASDAQ: GBNH) provides Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 620,000 TMS treatments to over 17,000 patients struggling with depression.
NewPace Ltd. is an Israeli medical device company developing breakthrough, out-of-the-box solutions for the cardiac rhythm management space.
Olympic Ophthalmics, Inc. is a clinical-stage medical device company leveraging expertise in ultrasound to discover, develop, and commercialize novel therapies to treat ocular diseases with high unmet needs. The company’s initial focus is to develop innovative devices to treat the signs and symptoms of Dry Eye Disease (DED).
REVA Medical is a leader in bioresorbable polymer technologies for vascular applications. Our mission is to restore patient health for life through the application of biomaterials in the development and sale of implantable medical devices.
Senseonics Holdings, Inc. (NYSE American: SENS) is an innovative medical device company developing transformative glucose monitoring products. The company's mission to help people with diabetes live their lives confidently and with ease.
Trice Medical, Inc., located in King of Prussia, PA, is a private diagnostics company focused on micro-invasive technologies and has pioneered fully-integrated, camera-enabled needle technologies that provide a clinical solution that is optimized for the physician’s office.
V-Wave Ltd. is developing a proprietary inter-atrial shunt for the treatment of heart failure. The percutaneous implantable device, which regulates left atrial pressure, is designed to relieve symptoms, reduce hospitalization, increase exercise capacity, and improve overall quality of life.